NASDAQ:AFMD - Nasdaq - NL0015001ZQ0 - Common Stock - Currency: USD
NASDAQ:AFMD (4/25/2025, 8:00:00 PM)
0.9347
+0.04 (+5.02%)
The current stock price of AFMD is 0.9347 USD. In the past month the price increased by 16.11%. In the past year, price decreased by -81.42%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.39 | 329.14B | ||
AMGN | AMGEN INC | 14.17 | 150.99B | ||
GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
NTRA | NATERA INC | N/A | 20.79B | ||
BIIB | BIOGEN INC | 7.22 | 17.39B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 76 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
AFFIMED NV
Im Neuenheimer Feld 582
Heidelberg BADEN-WUERTTEMBERG 69120 DE
CEO: Adi Hoess
Employees: 76
Company Website: https://www.affimed.com/
Investor Relations: https://www.affimed.com/investors
Phone: 49621560030
The current stock price of AFMD is 0.9347 USD. The price increased by 5.02% in the last trading session.
The exchange symbol of AFFIMED NV is AFMD and it is listed on the Nasdaq exchange.
AFMD stock is listed on the Nasdaq exchange.
11 analysts have analysed AFMD and the average price target is 12.24 USD. This implies a price increase of 1209.51% is expected in the next year compared to the current price of 0.9347. Check the AFFIMED NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AFFIMED NV (AFMD) has a market capitalization of 14.24M USD. This makes AFMD a Nano Cap stock.
AFFIMED NV (AFMD) currently has 76 employees.
AFFIMED NV (AFMD) has a resistance level at 1.45. Check the full technical report for a detailed analysis of AFMD support and resistance levels.
The Revenue of AFFIMED NV (AFMD) is expected to decline by -81.84% in the next year. Check the estimates tab for more information on the AFMD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AFMD does not pay a dividend.
AFFIMED NV (AFMD) will report earnings on 2025-05-21.
AFFIMED NV (AFMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.2).
The outstanding short interest for AFFIMED NV (AFMD) is 4.13% of its float. Check the ownership tab for more information on the AFMD short interest.
ChartMill assigns a technical rating of 1 / 10 to AFMD. When comparing the yearly performance of all stocks, AFMD is a bad performer in the overall market: 92.43% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to AFMD. AFMD has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months AFMD reported a non-GAAP Earnings per Share(EPS) of -5.2. The EPS increased by 42.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -175.1% | ||
ROE | -406.92% | ||
Debt/Equity | 0.35 |
ChartMill assigns a Buy % Consensus number of 84% to AFMD. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 40.97% and a revenue growth -81.84% for AFMD